Hybrid APC Therapy in Early Central Lung Cancer

This cohort study aims to investigate the clinical value of Hybrid APC for treatment of early central lung cancer.

Primary Outcome Measures

  • Successful remission rate: [ Time Frame: 3 months ]
    successful remission is defined as absence of intraepithelial neoplasia in biopsies of original locations at 3 months after HybridAPC upon follow up

Secondary Outcome Measures

  • Complications [ Time Frame: 3 months ]
    possible complications include perforation, bleeding, fever, stenosis, cough and etc.

Eligibility Criteria

Inclusion Criteria
bronchoscopy and fluorescence bronchoscopy found endoluminal growth lesions of upper segmental bronchus. AFB indicates malignant possibility.

Size ≤ 20 mm

Flat, nodule or polypoid type

Negative imaging: HRCT indicates no tumor in lung and lymph node enlargement; or PET-CT finds no lesions in lung or suspicious lymph node tumors involve.

Clinical stage: Tis or T1N0M0

High-grade intraepithelial neoplasia (including severe atypical dysplasia and carcinoma in situ) or squamous cancer confirmed by biopsy histopathology

High-frequency EBUS indicates the depth of lesions is cartilage endomembrane or internal part of adventitia of tracheal membranous part

Patients are not suitable for surgery or refuse surgery

Inform consent is available
Exclusion Criteria
Patients with severe cardiopulmonary dysfunction or other contraindication can not tolerate endoscopic examination and treatment

Severe bleeding tendency

Poor compliance

Unstable vital signs

Investigators consider subjects should not be included because of specific situations

« Mesothelioma Clinical Trials Main Page.

Source: the U.S. National Institutes of Health via ClinicalTrials.gov. Last updated: June 29th, 2018.

You can follow any responses to this entry through the RSS 2.0 feed.

Both comments and pings are currently closed.

Comments are closed.

Last update: January 19, 2018. 04:57:31 pm.